A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Serban, Corina ^a   Sahebkar, Amirhossein ^b,c   Ursoniu, Sorin ^a   Mikhailidis, Dimitri P ^d   Rizzo, Manfredi ^e   Lip, Gregory Y H ^f   Kees Hovingh, G ^g   Kastelein, John J P ^g   Kalinowski, Leszek ^h   Rysz, Jacek ⁱ   Banach, Maciej ⁱ  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N,N-DIMETHYLARGININE;

ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; HUMAN; META ANALYSIS; METABOLISM; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR ENDOTHELIUM;

ARGININE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929329882     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09902     Document Type: Review

References (50)

1. Margaritis, M., Channon, K. M. & Antoniades, C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxidants & redox signaling 20, 1198-1215 (2014).
2. Boger, R. H. & Ron, E. S. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Alternative medicine review: a journal of clinical therapeutic 10, 14-23 (2005).
3. Kielstein, A., Tsikas, D., Galloway, G. P. & Mendelson, J. E. Asymmetric dimethylarginine (ADMA) - A modulator of nociception in opiate tolerance and addiction?Nitric oxide: biology and chemistry/official journal of the Nitric Oxide Society 17, 55-59 (2007).
4. Pekarova, M. et al. Asymmetric dimethylarginine regulates the lipopolysaccharide-induced nitric oxide production in macrophages by suppressing the activation of NF-kappaB and iNOS expression. European journal of pharmacology 713, 68-77, doi:10.1016/j.ejphar.2013.05.001 (2013).
5. Valkonen, V.-P. et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. The Lancet 358, 2127-2128 (2001).
6. Böger, R. H., Maas, R., Schulze, F. & Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patient populations with a wide range of cardiovascular risk. Pharmacological Research 60, 481-487 (2009).
7. Kielstein, J. T., Frolich, J. C., Haller, H. & Fliser, D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 16, 1742-1745 (2001).
8. Siegerink, B. et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clinical research in cardiology: official journal of the German Cardiac Society 102, 193-202, doi:10.1007/s00392-012-0515-4 (2013).
9. Anderssohn, M., Schwedhelm, E., Luneburg, N., Vasan, R. S. & Boger, R. H. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease 7, 105-118, doi:10.1177/1479164110366053 (2010).
10. Schulze, F. et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. American heart journal 152, (493), . e491-493. e498 (2006).
11. Bode-Böger, S. M., Scalera, F. & Ignarro, L. J. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacology & therapeutics 114, 295-306 (2007).
12. van der Zwan, L. et al. Systemic inflammation is linked to low arginine and high ADMA plasma levels resulting in an unfavourable NOS substrate-to-inhibitor ratio: the Hoorn Study. Clinical science 121, 71-78 (2011).
13. Landim, M. B. P., Casella Filho, A. & Chagas, A. C. P. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics 64, 471-478 (2009).
14. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery 8, 336-341, doi:10.1016/j.ijsu.2010.02.007 (2010).
15. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials 17, 1-12 (1996).
16. Jadad, A. R. The merits of measuring the quality of clinical trials: is it becoming a Byzantine discussion?Transplant international: official journal of the European Society for Organ Transplantation 22, 1028, doi:10.1111/j.1432-2277.2009.00919.x (2009).
17. Moher, D. et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health technology assessment (Winchester, England) 3, i-iv, 1-98 (1998).
18. Sahebkar, A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutrition reviews 71, 822-835, doi:10.1111/nure.12081 (2013).
19. Higgins, J. P. & Green, S. Cochrane handbook for systematic reviews of interventions. Vol. 5 (Wiley Online Library, 2008).
20. Sahebkar, A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytotherapy research: PTR 28, 633-642, doi:10.1002/ptr.5045 (2014).
21. Sahebkar, A. Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA and cell biology 32, 188-198, doi:10.1089/dna.2012.1947 (2013).
22. Panichi, V. et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. Journal of nephrology 21, 38-44 (2008).
23. Eid, H. M., Eritsland, J., Larsen, J., Arnesen, H. & Seljeflot, I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166, 279-284 (2003).
24. Lu, T. M. et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American journal of cardiology 94, 157-161, doi:10.1016/j.amjcard.2004.03.052 (2004).
25. Nanayakkara, P. W. et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation 53, 41-50, doi:10.1053/j.ajkd.2008.06.016 (2009).
26. Vladimirova-Kitova, L. G. & Deneva-Koycheva, T. I. The effect of simvastatin on asymmetric dimethylarginine and flowmediated vasodilation after optimizing the LDL level: a randomized, placebo-controlled study. Vascular pharmacology 56, 122- 130, doi:10.1016/j.vph.2011.10.004 (2012).
27. Oguz, A. & Uzunlulu, M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. International heart journal 49, 303-311 (2008).
28. Young, J. M. et al. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. European journal of heart failure 10, 463-466, doi:10.1016/j.ejheart.2008.03.010 (2008).
29. Xia, W., Yin, Z., Li, J., Song, Y. & Qu, X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing and clinical electrophysiology:PACE 32, 1562-1566, doi:10.1111/j.1540-8159.2009.02554.x (2009).
30. Janatuinen, T. et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vascular medicine 8, 185-189 (2003).
31. Lu, T.-M. et al. Effect ofrosuvastatinon plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American journal of cardiology 94, 157-161 (2004).
32. Mangoni, A. A. The emerging role of symmetric dimethylarginine in vascular disease. Advances in clinical chemistry 48, 73-94 (2009).
33. Antoniades, C. et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. European heart journal 30, 1142-1150, doi:10.1093/eurheartj/ehp061 (2009).
34. Antoniades, C. et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 58, 93-98, doi:10.1161/HYPERTENSIONAHA.110.168245 (2011).
35. Tran, C. T., Leiper, J. M. & Vallance, P. The DDAH/ADMA/NOS pathway. Atherosclerosis. Supplements 4, 33-40 (2003).
36. Ito, A. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99, 3092-3095 (1999).
37. Wadham, C. & Mangoni, A. A. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert opinion on drug metabolism & toxicology 5, 303-319, doi:10.1517/17425250902785172 (2009).
38. Schneider, J. Y., Pham, V. V., Froelich, J. C. & Tsikas, D. DDAH activity is not associated with oxidative stress in elderly patients with peripheral arterial occlusive disease. Experimental gerontology 55, 159 (2014).
39. Tsikas, D. & Chobanyan, K. Pitfalls in the measurement of tissue DDAH activity: is DDAH sensitive to nitrosative and oxidative stress&quest. Kidney international 74, 969-969 (2008).
40. Zhang, G. G. et al. Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. Vascular pharmacology 48, 115-121, doi:10.1016/j.vph.2008.01.004 (2008).
41. Aydin, U. et al. Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology 60, 370-377, doi:10.1177/0003319708321102 (2009).
42. Grosso, A. F. et al. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetology & metabolic syndrome 6, 47, doi:10.1186/1758-5996-6-47 (2014).
43. Valkonen, V. P. et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atherosclerosis. Supplements 4, 19-22 (2003).
44. Jiang, J. L. et al. The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells. Biochemistry and cell biology=Biochimie et biologie cellulaire 85, 66-77, doi:10.1139/o06-146 (2007).
45. Ivashchenko, C. Y. et al. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. American journal of physiology. Heart and circulatory physiology 298, H251-258, doi:10.1152/ajpheart.00195.2009 (2010).
46. Lin, J. et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120, 261-273, doi:10.1016/j.cell.2004.11.043 (2005).
47. Dragan, S., Serban, M. C. & Banach, M. Proprotein Convertase Subtilisin/Kexin 9 Inhibitors: An Emerging Lipid-Lowering Therapy? Journal of cardiovascular pharmacology and therapeutics, doi:10.1177/1074248414539562 (2014).
48. Rashid, S. et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America 102, 5374-5379, doi:10.1073/pnas.0501652102 (2005).
49. Derkacz, A. et al. Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty. Archives of medical science: AMS 7, 444-448, doi:10.5114/aoms.2011.23410 (2011).
50. Goch, A., Banach, M., Mikhailidis, D. P., Rysz, J. & Goch, J. H. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clinical and experimental hypertension 31, 20-30, doi:10.1080/10641960802409846 (2009).